NLRP3炎症小体及其相关通路与动脉粥样硬化研究进展

动脉粥样硬化所导致的心血管病是人类致死致残的重要原因。炎症因素作为重要危险因素已得到研究者共识,越来越多的证据表明炎症参与了从早期内皮功能障碍到晚期斑块破裂的AS形成的各个阶段。CANTOS研究作为测试AS炎症假说的第一个大规模临床试验,为寻找IL-1β介导的炎症性AS的潜在治疗靶点提供依据。Nod样受体蛋白3炎症小体作为固有免疫系统的一种识别受体,可引起半胱氨酸天冬氨酸特异性蛋白酶1激活,产生和释放成熟的促炎因子白细胞介素1-β,参与炎症反应发生发展。本文对胆固醇结晶,氧化低密度脂蛋白,血流动力学改变,斑块内细胞代谢方式变化等对NLRP3炎症体激活机制以及NLRP3炎症小体的激活途径和临床治疗方法进行综述,以期通过对NLRP3及其相关通路的研究,为临床动脉粥样硬化治疗提供新思路。     

一个日益重要的冠心病标志物———新蝶呤

动脉粥样硬化是一种慢性炎症过程,炎症反应在动脉粥样斑块的形成、发展、稳定性丧失和斑块破裂过程中都起着非常重要的作用,贯穿于动脉粥样硬化的各个环节。从早期的脂质条纹到进一步的动脉粥样病变及血栓性并发症都能见到炎症细胞的浸润,其中又以激活的巨噬细胞尤为重要。新蝶呤是巨噬细胞激活后的代谢产物,它不仅是巨噬细胞激活的炎症标志物,还参与多种调节氧化平衡的生化途径,增加氧化应激水平,促进动脉粥样硬化的进展,是斑块不稳定性及不良性心血管事件的独立预测因子。在临床上,降低血清新蝶呤水平可以降低冠心病患者发生危险事件的风险。因此,新蝶呤对冠心病的诊断和治疗都有重要意义。本文将对新蝶呤在冠心病中的角色做一综述。     

血管紧张素Ⅱ对单核/巨噬细胞的致炎作用及其药物干预

动脉粥样硬化斑块形成和破裂的重要原因是病变部位炎症反应的加剧,而巨噬细胞作为粥样斑块内主要的炎症细胞,在炎症反应中起主导作用.血管紧张素Ⅱ作为一种重要促炎因子,促进单核/巨噬细胞浸润于动脉粥样硬化斑块,激活斑块内的巨噬细胞,上调各种炎症因子,从而参与动脉粥样硬化的发生发展过程.血管紧张素转化酶抑制剂、AngⅡ受体阻断剂、调血脂药、干扰素-β、雌激素等药物可减轻血管紧张素Ⅱ诱导的血管壁炎症反应,发挥抗动脉粥样硬化作用.     

炎症小体在动脉粥样硬化发生发展中的研究进展

炎症小体(inflammasome)是免疫细胞内由多种蛋白质所组成的复合体,属于胞浆型模式识别受体(pattern recognition receptor,PRR)。它作为固有免疫系统的重要组分在机体免疫反应和疾病发生过程中具有重要作用。近年来的研究表明炎症小体是炎症免疫反应的核心。由于能被多种类型的病原体或危险信号所激活,NLRP3(NOD样受体蛋白-3)炎症小体在多种疾病过程中,包括动脉粥样硬化症、家族性周期性自身炎症反应、阿尔海默茨病和2型糖尿病等都发挥了关键作用。因此,NLRP3(NOD样受体蛋白-3)炎症小体可能为各种炎症性疾病,包括动脉粥样硬化的治疗提供新的靶点。本文将对炎症小体在动脉粥样硬化发生发展中发挥的作用进行综述。     

NLRP3炎症小体介导的炎症相关疾病研究进展

炎症小体在炎症相关疾病的发生发展中发挥重要作用,其中NLRP3炎症小体能够被多种病原相关分子模式(pathogen-associated molecular patterns,PAMPs)和损伤相关分子模式(damage-associated molecular patterns,DAMPs)激活,进而活化caspase-1,释放成熟形式的IL-1β和IL-18,引起机体的炎症反应,并参与多种疾病的发生发展,包括2型糖尿病、痛风、动脉粥样硬化、神经退行性疾病、肿瘤、炎症性肠病等。因此,研究NLRP3炎症小体的作用机制不仅有助于加深对炎症性疾病发生发展的认识,也为寻找此类疾病的潜在治疗靶点提供了新的思路。就NLRP3炎症小体在炎症相关疾病中的研究进展作一综述。     

自噬与NLRP3炎症小体的相互作用

自噬是一种普遍存在的细胞内稳态机制,通过将细胞质成分运送到溶酶体进行降解,以抵抗病原体感染并促进氨基酸循环。NLRP3炎症小体是一种多蛋白复合物,在多种内源和外源性刺激下被激活,介导促炎细胞因子的分泌,参与炎症的发生。自噬功能失调可导致NLRP3炎症小体的过度激活,引起各种炎症性疾病以及癌症的发生。自噬作为NLRP3炎症小体的一种重要调节方式,可以通过去除NLRP3炎症小体的激活信号、包裹和降解其成分来调控炎症小体。此外,自噬在调控IL-1β的分泌中也起着重要作用。同样,NLRP3炎症小体也调控自噬过程,以平衡宿主防御所需的适当炎症反应以及预防过度、有害炎症的发生。因此,阐明这两个生物学过程之间的相互作用,能够加深对相关疾病发病机制的认识,为疾病治疗及药物研发提供新的思路和理论基础。     

NLRP3炎症小体与2型糖尿病的研究进展

NLRP3炎症小体作为固有免疫系统的重要组成部分,在2型糖尿病的发病过程中起着重要作用,而白细胞介素1β(IL-1β)是介导其发挥作用的关键因子。核糖体蛋白质合成、嘌呤受体P2X7、活性氧敏感的硫氧还原蛋白相互作用蛋白(TXNIP)与NLRP3炎症小体激活密切相关。肥胖时胰岛素作用的靶组织中NLRP3、IL-1β表达均增高,其介导的炎症反应在胰岛β细胞功能障碍、凋亡以及胰岛素抵抗发生过程中起关键作用。NLRP3炎症小体被多种途径激活,从而上调胰岛和脂肪组织中IL-1β的表达,促进胰岛β细胞凋亡及胰岛素抵抗的发生发展,导致糖尿病的产生。     

食源性致病菌激活NLRP3炎症小体及食源性功能物质的抑制机理研究进展

食源性致病菌感染是引起食源性疾病的首要因素,严重影响人类健康。炎症小体通过识别受体感知入侵宿主的危险信号进而组装形成多聚蛋白复合物,从而诱导炎症反应,是先天免疫系统中识别食源性病原菌感染和清除病原体的重要防线。NLRP3炎症小体是位于胞内的炎症反应平台,可以感知多种病原微生物的侵袭,在先天性免疫反应中起着至关重要的作用。食源性致病菌感染常引起NLRP3炎症小体的异常激活,介导多种炎症性疾病的发生和发展,因此,许多抗炎研究中常常以NLRP3炎症小体作为靶点。本文总结了食源性致病菌及其代谢产物激活NLRP3炎症小体的分子机制,以及天然产物和膳食功能物质抑制NLRP3炎症小体激活的机理,为治疗炎症性疾病、开发缓解致病菌诱导的炎症反应的功能化合物提供新的思路。     

Nek7与NLRP3炎性小体激活机制的研究进展

目前,Nod样受体蛋白3(nod-like receptor protein 3,NLRP3)炎性小体在免疫与人类疾病中的重要性已经得到公认,但NLRP3炎性小体的具体激活机制尚不清楚。NIMA相关蛋白激酶7(NIMA-related kinase 7,Nek7)参与NLRP3炎性小体激活,最终导致白介素IL-1β、IL-18的成熟及分泌。同时Nek7也被证实参与有丝分裂纺锤体形成和中心体的分离,且发现NLRP3炎性小体的激活和有丝分裂不能同时发生。因此,Nek7可能作为有丝分裂和NLRP3炎性小体激活两者之间的转换。本文就Nek7及NLRP3炎性小体的激活关系做一综述,以期为炎症性疾病提供新的治疗方向。     

自噬与NLRP3炎症小体激活间的相互作用

自噬作为真核生物细胞遭遇各种应激压力时发生的一种基本应答方式,参与细胞的多种生命活动,使细胞在各种应激条件下维持一种动态平衡状态。NOD样受体家族核苷酸结合寡聚化结构域样受体3（NOD-like receptor family,pyrin domain containing 3,NLRP3）炎症小体,是生物体内防御病原微生物的固有免疫防御系统的重要组成部分。NLRP3炎症小体通过激活胱天蛋白酶-1（caspase-1）,从而促进白细胞介素-1β（interleukin-1,IL-1β）和白细胞介素-18（interleukin-18,IL-18）等促炎细胞因子的成熟和分泌,继而介导炎症的发生。众多研究表明,自噬能够负向或正向调控NLRP3炎症小体的激活。同时,NLRP3炎症小体也会逆向影响自噬的作用。本文对自噬包括选择性自噬与NLRP3炎症小体激活的相互作用,以及通过激活自噬抑制NLRP3炎症小体,从而在炎症相关疾病治疗中的应用进行综述。     

Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation

Background

Chronic inflammation of the arterial wall is a key element in the pathogenesis of atherosclerosis, yet the factors that trigger and sustain the inflammation remain elusive. Inflammasomes are cytoplasmic caspase-1-activating protein complexes that promote maturation and secretion of the proinflammatory cytokines interleukin(IL)-1β and IL-18. The most intensively studied inflammasome, NLRP3 inflammasome, is activated by diverse substances, including crystalline and particulate materials. As cholesterol crystals are abundant in atherosclerotic lesions, and IL-1β has been linked to atherogenesis, we explored the possibility that cholesterol crystals promote inflammation by activating the inflammasome pathway.

Principal Findings

Here we show that human macrophages avidly phagocytose cholesterol crystals and store the ingested cholesterol as cholesteryl esters. Importantly, cholesterol crystals induced dose-dependent secretion of mature IL-1β from human monocytes and macrophages. The cholesterol crystal-induced secretion of IL-1β was caspase-1-dependent, suggesting the involvement of an inflammasome-mediated pathway. Silencing of the NLRP3 receptor, the crucial component in NLRP3 inflammasome, completely abolished crystal-induced IL-1β secretion, thus identifying NLRP3 inflammasome as the cholesterol crystal-responsive element in macrophages. The crystals were shown to induce leakage of the lysosomal protease cathepsin B into the cytoplasm and inhibition of this enzyme reduced cholesterol crystal-induced IL-1β secretion, suggesting that NLRP3 inflammasome activation occurred via lysosomal destabilization.

Conclusions

The cholesterol crystal-induced inflammasome activation in macrophages may represent an important link between cholesterol metabolism and inflammation in atherosclerotic lesions.     

Oxidized low-density lipoprotein induces secretion of interleukin-1β by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation

Oxidized low-density lipoprotein (ox-LDL) is a critical mediator of atherogenesis. Macrophage uptake of ox-LDL and their subsequent development into foam cells is the principal event in atherosclerosis. Interleukin-1β (IL-1β), a prototypic multifunctional cytokine involved in inflammation, has an important effect on the pathogenesis and progression of atherosclerosis. Here we show that the phagocytosis of ox-LDL can induce human macrophages to secrete IL-1β by activating the NLRP3 inflammasome, and we further show that the activation of the NLRP3 inflammasome is dependent on the generation of reactive oxygen species and is related to the cathepsin B pathway. Furthermore, ox-LDL can upregulate the expression of the pro-IL-1β protein, thus priming IL-1β secretion. Therefore, our results suggest that the role of ox-LDL in atherosclerosis-related inflammation may involve the activation of the NLRP3 inflammasome.     

Autophagy links inflammasomes to atherosclerotic progression

We investigated the role of autophagy in atherosclerosis. During plaque formation in mice, autophagic markers colocalized predominantly with macrophages (mφ). Atherosclerotic aortas had elevated levels of p62, suggesting that dysfunctional autophagy is characteristic of plaques. To determine whether autophagy directly influences atherogenesis, we characterized Beclin-1 heterozygous-null and mφ-specific ATG5-null (ATG5-mφKO) mice, commonly used models of autophagy haploinsufficiency and deficiency, respectively. Haploinsufficent Beclin-1 mice had no atherosclerotic phenotype, but ATG5-mφKO mice had increased plaques, suggesting an essential role for basal levels of autophagy in atheroprotection. Defective autophagy is associated with proatherogenic inflammasome activation. Classic inflammasome markers were robustly induced in ATG5-null mφ, especially when coincubated with cholesterol crystals. Moreover, cholesterol crystals appear to be increased in ATG5-mφKO plaques, suggesting a potentially vicious cycle of crystal formation and inflammasome activation in autophagy-deficient plaques. These results show that autophagy becomes dysfunctional in atherosclerosis and its deficiency promotes atherosclerosis in part through inflammasome hyperactivation.     

Inhibition of the NLRP3 inflammasome attenuates foam cell formation of THP-1 macrophages by suppressing ox-LDL uptake and promoting cholesterol efflux

The NOD-like receptor family, pyrin domain–containing protein 3 (NLRP3) inflammasome plays an important role in the development of atherosclerosis. The activated NLRP3 inflammasome has been reported to promote macrophage foam cell formation, but not all studies have obtained the same result, and how NLRP3 inflammasome is involved in the formation of foam cells remains elusive. We used selective NLRP3 inflammasome inhibitors and NLRP3-deficient THP-1 cells to assess the effect of NLRP3 inflammasome inhibition on macrophage foam cell formation, oxidized low-density lipoprotein (ox-LDL) uptake, esterification, and cholesterol efflux, as well as the expression of associated proteins. Inhibition of the NLRP3 inflammasome attenuated foam cell formation, diminished ox-LDL uptake, and promoted cholesterol efflux from THP-1 macrophages. Moreover, it downregulated CD36, acyl coenzyme A: cholesterol acyltransferase-1 and neutral cholesterol ester hydrolase expression; upregulated ATP-binding cassette transporter A1 (ABCA1) and scavenger receptor class B type I (SR-BI) expression; but had no effect on the expression of scavenger receptor class A and ATP-binding cassette transporter G1. Collectively, our findings show that inhibition of the NLRP3 inflammasome decreases foam cell formation of THP-1 macrophages via suppression of ox-LDL uptake and enhancement of cholesterol efflux, which may be due to downregulation of CD36 expression and upregulation of ABCA1 and SR-BI expression, respectively.     

固有免疫应答与动脉粥样硬化关系的研究进展

固有免疫应答在动脉粥样硬化(atherosclerosis,As)的发生和发展中起重要作用．固有免疫应答细胞,包括单核/巨噬细胞、肥大细胞、自然杀伤细胞、中性粒细胞和树突状细胞,是机体抵御微生物和异物入侵的第一道防线．这些细胞广泛参与As中泡沫细胞形成、斑块内基质降解、细胞凋亡、血管新生和斑块破裂等事件．模式识别受体是免疫细胞上识别病原体(或某些内源性成分)相关分子模式的一类受体分子,包括Toll样受体和NOD样受体,介导固有免疫应答反应．Toll样受体在固有免疫应答细胞中具有不同程度的表达,在As中具有不同的作用,如TLR2和TLR4对As起促进作用,而TLR3具有As保护作用．NLRP3炎性体与动脉血管壁的早期损伤有关．对固有免疫应答细胞及模式识别受体在As形成中的作用进行深入研究,不仅有助于理解As的形成过程,而且还能为临床上防治心血管类疾病提供了新的治疗靶点和诊断指标．     

Basic calcium phosphate crystals induce monocyte/macrophage IL-1β secretion through the NLRP3 inflammasome in vitro

Basic calcium phosphate (BCP) crystals are associated with severe osteoarthritis and acute periarticular inflammation. Three main forms of BCP crystals have been identified from pathological tissues: octacalcium phosphate, carbonate-substituted apatite, and hydroxyapatite. We investigated the proinflammatory effects of these BCP crystals in vitro with special regard to the involvement of the NLRP3-inflammasome in THP-1 cells, primary human monocytes and macrophages, and mouse bone marrow-derived macrophages (BMDM). THP-1 cells stimulated with BCP crystals produced IL-1β in a dose-dependent manner. Similarly, primary human cells and BMDM from wild-type mice also produced high concentrations of IL-1β after crystal stimulation. THP-1 cells transfected with short hairpin RNA against the components of the NLRP3 inflammasome and mouse BMDM from mice deficient for NLRP3, apoptosis-associated speck-like protein, or caspase-1 did not produce IL-1β after BCP crystal stimulation. BCP crystals induced macrophage apoptosis/necrosis as demonstrated by MTT and flow cytometric analysis. Collectively, these results demonstrate that BCP crystals induce IL-1β secretion through activating the NLRP3 inflammasome. Furthermore, we speculate that IL-1 blockade could be a novel strategy to inhibit BCP-induced inflammation in human disease.     

Mechanisms of NLRP3 priming in inflammaging and age related diseases

The NLRP3 inflammasome is a vital part of the innate immune response, whilst its aberrant activation drives the progression of a number of non-communicable diseases. Thus, NLRP3 inflammasome assembly must be tightly controlled at several checkpoints. The priming step of NLRP3 inflammasome activation is associated with increased NLRP3 gene expression, as well as post-translational modifications that control NLRP3 levels and licence the NLRP3 protein for inflammasome assembly. Increasing life expectancy in modern society is accompanied by a growing percentage of elderly individuals. The process of aging is associated with chronic inflammation that drives and/or worsens a range of age related non-communicable conditions. The NLRP3 inflammasome is known to contribute to pathological inflammation in many settings, but the mechanisms that prime NLRP3 for activation throughout aging and related co-morbidities have not been extensively reviewed. Here we dissect the biochemical changes that occur during aging and the pathogenesis of age related diseases and analyse the mechanisms by which they prime the NLRP3 inflammasome, thus exacerbating inflammation.